Cutaquig market seen growing as home infusion and immune disorder diagnoses rise

The market for Cutaquig, a subcutaneous immunoglobulin therapy for primary immunodeficiency, is expanding on rising diagnosis rates, wider use of home-based care and more infectious and age-related immune disorders. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through the forecast period.

Why it matters: - Cutaquig is used to replace antibodies in patients with primary immunodeficiency disorders, a group of conditions that weaken the body’s ability to fight infections. - Demand for home-administered immune therapies matters because patients and providers are shifting away from hospital-based treatment when possible. - The market outlook reflects broader pressure from rising immune disorder diagnosis, infectious disease burden and an aging population.

What happened: - The Business Research Company released a Cutaquig market forecast report on Nov. 2, 2026. - The report covers Cutaquig, a subcutaneous immunoglobulin therapy, and its market outlook through 2026. - The company said North America was the largest Cutaquig market in 2025. - The company said Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report includes regional analysis for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report is available as a free sample. - The full report is also available online.

The details: - Market growth is being supported by advances in immunoglobulin therapy and greater awareness of primary immunodeficiency disorders. - Hospital-based immune disorder management, expansion of plasma fractionation and regulatory approvals for subcutaneous immunoglobulin therapies have also pushed the market higher. - Forecast growth is tied to wider adoption of home infusion models, higher prevalence of immune disorders and a stronger focus on quality of life. - Specialty immunology clinics and innovations in plasma-derived biologics are adding to demand. - Patients and healthcare providers are increasingly choosing subcutaneous immunoglobulin therapies like Cutaquig because home treatment offers more convenience and autonomy than hospital care. - Improvements in self-administration techniques are helping support that shift. - Expanding primary immunodeficiency diagnosis rates are broadening the patient pool eligible for Cutaquig. - Cutaquig is designed to treat primary immunodeficiency disorders by delivering essential antibodies that help reduce recurrent infections. - Home administration is one of Cutaquig’s main advantages for chronic immune deficiency care. - Rising immunodeficiency prevalence is a major demand driver. - The report points to aging populations, environmental pollution, unhealthy lifestyles and more chronic illness as contributors to that increase. - Better diagnostic capabilities are also expanding the number of patients identified for immunoglobulin replacement therapy. - The UK National Health Service reported more than 6,678 patients receiving immunoglobulin therapy for primary and secondary immunodeficiencies during 2023–2024, according to the report. - Infectious disease prevalence is also lifting demand for immune-supportive therapies. - Health Equity Matters, an Australian non-profit, said in 2024 that people living with HIV rose 3.9%, from 28,870 at the end of 2022 to 30,010 at the end of 2023. - The report says older adults are another key driver because immune function declines with age. - The Population Reference Bureau projected in January 2024 that the number of Americans age 65 and older would rise from 58 million in 2022 to 82 million by 2050. - That same projection puts the share of the U.S. population age 65 and older at 23% by 2050, up from 17%. - The 2026 report package also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and trend analysis. - The report lists contact information for Saumya Sahay and The Business Research Company, along with social media links, including LinkedIn, Facebook and X.

Between the lines: - The report frames Cutaquig as part of a broader move toward decentralized care, where patients manage chronic immune conditions outside hospitals. - The strongest demand signals come from structural trends, not a single product launch, which suggests the market is being shaped by long-term healthcare needs. - The inclusion of regional scoring tools and dashboards signals that buyers are looking for more granular investment and commercial planning data.

What's next: - Adoption is likely to keep rising as more patients are diagnosed and more care moves into home settings. - Market growth will likely track the spread of specialty immunology clinics, continued plasma biologics innovation and ongoing increases in immune disorder prevalence. - The fastest gains are expected in Asia-Pacific if the forecast holds.

The bottom line: - Cutaquig is positioned to benefit from a larger shift toward home-based treatment for immune disorders, with diagnosis growth, aging populations and infectious disease pressure all supporting demand.